Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: A population-based follow-up study

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 6, 2009, Pages 515-522

  Horsdal, Henriette T ^a,b   Johnsen, Søren Paaske ^a   Søndergaard, Flemming ^a   Jacobsen, Jacob ^a   Thomsen, Reimar W ^a   Schmitz, Ole ^b   Sørensen, Henrik T ^a   Rungby, Jørgen ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Epidemiology; Myocardial infarction; Prognosis; Sulfonylureas; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ADULT; AGED; ARTICLE; DRUG USE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SELECTION BIAS; STATISTICS, NONPARAMETRIC; SULFONYLUREA COMPOUNDS; TIME FACTORS;

EID: 68849107167     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.971     Document Type: Article

References (44)

1. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19(Suppl. 2): 789-830.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Brady PA, Al Suwaidi J, Kopecky SL, Terzic A. Sulfonylureas and mortality in diabetic patients after myocardial infarction. Circulation 1998; 97: 709-710. (Pubitemid 28090971)
4. Danchin N, Charpentier G, Ledru F, et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry. Diabetes Metab Res Rev 2004; 21: 143-149. (Pubitemid 39331900)
5. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 1998; 21: 637-640. (Pubitemid 28172948)
6. Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increasedmetformin-associated mortality over a 5-year follow-up. Cardiology 1999; 91: 195-202. (Pubitemid 29454258)
7. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124. (Pubitemid 29064081)
8. Gustafsson I, Hildebrandt P, Seibaek M, et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. Eur Heart J 2000; 21: 1937-1943. (Pubitemid 30943691)
9. Gustafsson I, Hildebrandt P, Seibaek M, et al. Prognosis of diabetic patients with MI. Cardiol Rev 2001; 18: 24-27.
10. Halkin A, Roth A, Jonas M, Behar S. Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis 2001; 12: 177-184. (Pubitemid 34071084)
11. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22: 79-84. (Pubitemid 12162120)
12. Jollis JG, Simpson RJ Jr, Cascio WE, Chowdhury MK, Crouse JR III, Smith SC Jr. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138: S376-S380. (Pubitemid 29523302)
13. Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000; 21: 220-229. (Pubitemid 30137807)
14. Meier JJ, Deifuss S, Klamann A, Schmiegel W, Nauck MA. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes 2003; 111: 344-350. (Pubitemid 37254611)
15. O'Keefe JH, Blackstone EH, Sergeant P, McCallister BD. The optimal mode of coronary revascularization for diabetics. A risk-adjusted long-term study comparing coronary angioplasty and coronary bypass surgery. Eur Heart J 1998; 19: 1696-1703. (Pubitemid 28524189)
16. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985; 8: 230-234. (Pubitemid 15071437)
17. Ulvenstam G, Aberg A, Bergstrand R, et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes 1985; 34: 787-792. (Pubitemid 15018663)
18. Riveline JP, Danchin N, Ledru F, Varroud-Vial M, Charpentier G. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. Diabetes Metab 2003; 29: 207-222. (Pubitemid 36807432)
19. Johnsen SP, Monster TB, Olsen ML, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006; 13: 134-140. (Pubitemid 43755123)
20. Frank L. Epidemiology. When an entire country is a cohort. Science 2000; 287: 2398-2399.
21. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-268. (Pubitemid 29299976)
22. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612. (Pubitemid 24986974)
23. Statistics Denmark. IDA - An Integrated Database for Labour Market Research. Statistics Denmark: Copenhagen, 1991.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
25. Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol 2006; 48: 2192-2194. (Pubitemid 44855412)
26. Sørensen HT, Lash TL, Rothman KJ. Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 2006; 44: 1075-1082. (Pubitemid 44748358)
27. Madsen M, Balling H, Eriksen LS. The validity of the diagnosis of acute myocardial infarction in 2 registries: the Heart Registry compared to the National Patient Registry. Ugeskr Laeger 1990; 152: 308-314.
28. Monami M, Luzzi C, Lamanna C, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-482. (Pubitemid 44774052)
29. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007; 23: 479-484. (Pubitemid 47520905)
30. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998; 31: 950-956. (Pubitemid 28212491)
31. Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 2003; 46: 875-891. (Pubitemid 36961311)
32. Loubani M, Fowler A, Standen NB, Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur J Pharmacol 2005; 515: 142-149. (Pubitemid 40779279)
33. Flynn DM, Smith AH, Treadway JL, et al. The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits. Cardiovasc Drugs Ther 2005; 19: 337-346.
34. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999; 20: 439-446. (Pubitemid 29116540)
35. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90: 700-705. (Pubitemid 24242735)
36. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004; 18: 113-119.
37. Horimoto H, Nakai Y, Mieno S, Nomura Y, Nakahara K, Sasaki S. Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning. J Surg Res 2002; 105: 181-188. (Pubitemid 34765325)
38. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation 2001; 103: 3111-3116.
39. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia 1999; 42: 845-848.
40. Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9-12. (Pubitemid 38064530)
41. Kimoto K, Suzuki K, Kizaki T, et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003; 303: 112-119. (Pubitemid 36338215)
42. O'Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complications 2000; 14: 201-206. (Pubitemid 30686256)
43. Horsdal HT, Johnsen SP, Søndergaard F, Rungby J. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia 2008; 51: 567-574.
44. Madsen M, Rasmussen S. Myocardial infarction and angina pectoris - incidence and mortality. In Heart Statistics 2004 (3rd edn). The Danish Heart Foundation and the National Institute of Public Health: Copenhagen, 2004; 153-176.